Anson Funds Management LP purchased a new stake in Zentek Ltd. (NASDAQ:ZTEK - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 154,933 shares of the company's stock, valued at approximately $145,000. Anson Funds Management LP owned about 0.15% of Zentek as of its most recent filing with the SEC.
Separately, Two Sigma Securities LLC bought a new position in shares of Zentek during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 0.77% of the company's stock.
Zentek Price Performance
ZTEK stock traded up $0.00 during trading on Wednesday, hitting $1.56. 137,262 shares of the company's stock traded hands, compared to its average volume of 43,081. The business has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.06. Zentek Ltd. has a 52 week low of $0.50 and a 52 week high of $1.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.83. The stock has a market capitalization of $163.11 million, a price-to-earnings ratio of -22.32 and a beta of 0.73.
Zentek (NASDAQ:ZTEK - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. Zentek had a negative net margin of 16,555.32% and a negative return on equity of 58.13%.
Zentek Company Profile
(
Free Report)
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.
Featured Articles
Before you consider Zentek, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.
While Zentek currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
